homepage-top-section

As part of the collaboration, the companies will use Prellis Biologics’ externalised human immune system (EXIS) which is based on human lymph node organoids (LNO). The human antibody

The latest move follows the identification of various gene signatures that predict a tumour’s possible response to these drug candidates of Lantern. LP-184 is being analysed as a

The laboratory of Steven Rosenberg, chief of surgery at the NCI, discovered these TCRs. NCI is an institute of the National Institutes of Health (NIH). Neogene’s neoantigen TCR

The collaboration will see the base editing programmes to be evaluated leverage Beam’s in vivo delivery technologies. These technologies use messenger RNA (mRNA) and lipid nanoparticles (LNP) to

The partnership aims to develop new drugs with predictable manufacturing and clinical behaviour. Under the deal, Amgen will make an upfront investment of $50m for the first five

The agreement also includes the lead candidate, OV350, which showed promising in-vitro and in-vivo proof of concept in resistant forms of epilepsy. The early-stage compound directly targets and

The move comes after the Drugs Controller General of India (DCGI) granted emergency use authorization (EUA) for the vaccine, dubbed ‘The World’s COVID-19 Vaccine’. Corbevax technology was engineered

Molnupiravir is an orally administered form of a potent ribonucleoside analogue that blocks the SARS-CoV-2 replication. It is planned to be sold under the trademark Lagevrio in the

A fully human monoclonal antibody, Saphnelo targets subunit 1 of the type one interferon (type 1 IFN) receptor, blocking the type 1 IFN’s activity. It has been recommended